AXSM vs. JAZZ, BNTX, TEVA, GMAB, SMMT, ASND, VTRS, RDY, QGEN, and BBIO
Should you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include Jazz Pharmaceuticals (JAZZ), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), and BridgeBio Pharma (BBIO). These companies are all part of the "medical" sector.
Axsome Therapeutics vs. Its Competitors
Jazz Pharmaceuticals (NASDAQ:JAZZ) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.
Jazz Pharmaceuticals has a net margin of -9.91% compared to Axsome Therapeutics' net margin of -49.88%. Jazz Pharmaceuticals' return on equity of 5.02% beat Axsome Therapeutics' return on equity.
In the previous week, Jazz Pharmaceuticals had 5 more articles in the media than Axsome Therapeutics. MarketBeat recorded 20 mentions for Jazz Pharmaceuticals and 15 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 1.58 beat Jazz Pharmaceuticals' score of 1.37 indicating that Axsome Therapeutics is being referred to more favorably in the news media.
89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 4.3% of Jazz Pharmaceuticals shares are held by company insiders. Comparatively, 22.3% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Jazz Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Jazz Pharmaceuticals has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.
Jazz Pharmaceuticals currently has a consensus price target of $178.67, indicating a potential upside of 42.68%. Axsome Therapeutics has a consensus price target of $177.86, indicating a potential upside of 52.30%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.
Summary
Jazz Pharmaceuticals beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Axsome Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Axsome Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:AXSM) was last updated on 9/16/2025 by MarketBeat.com Staff
Free AXSM Stock Alerts